New drug approvals - December 2022

  • Please click here for a list of summary reports of benefit-risk assessments.

Product Name

LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG

Active Ingredient

Rosuvastatin, ezetimibe

Application type

NDA-2: New combination

Product Registrant

ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED

Date of Approval

06/12/2022

Registration No.

SIN16650P, SIN16651P

Indications:

LYPSTAPLUS® is indicated as adjunct to diet for treatment of primary hypercholesterolemia as substitution therapy in adult patients adequately controlled with the individual substances given concurrently at the same dose level as in the fixed dose combination, but as separate products.


Healthcare professional, Industry member, Therapeutic Products
Published:

New Drug Approvals